Fig 6. MTX treatment does not affect the expression of the PGE2 degrading enzyme 15-PGDH in HSF.
A) 15-PGDH mRNA levels from HSF stimulated by PIC 100μg/mL and 10μg/mL or infected by CHIKV at MOI 10−1 and 10−4 for 6 h and 24 h in the absence and presence of MTX 1μM treatment were evaluated by qRT-PCR. B) Relative gene expression of 15-PGDH from HSF after IFNβ 1000U/mL and 100U/mL exposure in the presence and absence of MTX 1μM treatment and post-IL-1β 1ng/mL and TNFα 10ng/mL stimulation in the presence or not of DXM 1μM treatment for 6h and 24h as assessed by qRT-PCR. All experiments were done in triplicates. Results are expressed as mean ± standard error and presented as normalized fold induction vs control. *: p-values ≤ 0.05, **: p-values ≤ 0.01 and ***: p-values ≤ 0.001 represent significant difference from controls by one-way ANOVA followed by the Bonferroni’s test analysis. #: p-values ≤ 0.05, ##: p-values ≤ 0.01 signifies statistical difference of samples treated with the drug (MTX or DXM) compared to untreated samples under the different stimulatory conditions by Student’s t-test.